 contralater primari tumor breast cancer patient random trial adjuv tamoxifen therapi prophylact treatment anti-estrogen tamoxifen risk breast cancer estrogen promot pathogenesi diseas articl result incid contralater new primari tumor postmenopaus breast cancer patient random trial adjuv tamoxifen therapi year surgeri versu adjuv endocrin therapi median follow-up year rang year signific reduct contralater breast cancer patient tamoxifen group versu control patient versu case cumul incid year tamoxifen group control group analysi rel hazard contralater tumor time benefit tamoxifen therapi first year risk reduct entir follow-up period year cessat treatment signific differ number contralater cancer patient year treatment confid interv rel hazard wide proport estrogen receptor-neg contralater breast cancer tamoxifen group control group differ group recurrence-fre surviv time diagnosi contralater cancer